Project Grant R01HL183867
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $873K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $232,836 on December 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomarkers of ischemic risk in adults with sickle cell disease using non-invasive quantitative neuroimaging methods. The research uses arterial spin labeling MRI and other quantitative imaging techniques to test hypotheses regarding cerebral oxygen utilization in patients with sickle cell disease...
- The National Heart, Lung, and Blood Institute awarded $1.834 million to St. Jude Children's Research Hospital Inc. on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test senescence-targeting therapies for improving hematopoietic stem cell function and mobilization in sickle cell disease. The research addresses pathologic bone marrow stress in sickle cell disease patients, which damages and depletes hematopoietic stem and progenitor cells and selects for...
- The National Heart, Lung, and Blood Institute awarded Duke University $238,516 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct admixture mapping of genetic modifiers in sickle cell disease. The research leverages the National Heart, Lung, and Blood Institute's TOPMed program, which includes multiple cross-sectional adult sickle cell disease cohorts totaling more than 4,000 participants with whole genome sequencing data and extensive clinical...
- The National Heart, Lung, and Blood Institute awarded the University of Tennessee Health Science Center $253,395 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify genetic modifiers of acute kidney injury in sickle cell disease. The award funds research evaluating candidate genetic variants—apolipoprotein L1 (APOL1), hemeoxygenase-1 (HMOX1), BCL11A, and alpha thalassemia—for their association with acute kidney injury (AKI) in a well-genotyped and...
- The National Heart, Lung, and Blood Institute awarded Emory University $797,648 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate red blood cell-bound cell-free DNA as a predictor of acute anemia in sickle cell disease. The research examines whether elevated levels of cell-free DNA released during vaso-occlusive complications in sickle cell disease bind to toll-like receptor 9 (TLR9) on red blood cells, thereby modulating red blood cell clearance...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $190,188 on April 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate biomarkers and predictors of treatment response in chronic anemia associated with sickle cell disease. The research evaluates the impact of anemia therapies—including hydroxyurea and blood transfusions—on cerebral tissue oxygenation and hemorheological biomarkers (blood viscosity and red blood cell...
- The National Heart, Lung, and Blood Institute awarded Yale University $313,649 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to derive and validate a clinical prediction rule identifying febrile children and adolescents with sickle cell disease at low risk for bacteremia. The project addresses overtreatment of febrile children with sickle cell disease in emergency departments. Existing clinical guidelines recommend aggressive evaluation for bacteremia due...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $171,488 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a nationwide examination of access to comprehensive care in sickle cell disease. The research uses national Medicaid insurance claims data to address two analytic aims. The first aim identifies three groups of people with sickle cell disease—those who do not receive care from a...
- The National Heart, Lung, and Blood Institute awarded Emory University $1,288,327 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on red blood cell survival in recipients with sickle cell disease. The research evaluates the impact of donor and recipient factors on transfused red blood cell (RBC) survival in sickle cell disease patients and examines mechanisms contributing to RBC clearance. The study proposes an experimental,...
- The National Heart, Lung, and Blood Institute awarded Rutgers The State University of New Jersey, School of Nursing, $117,750 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic profiling and neurocognitive assessment to uncover stroke mechanisms in adults with sickle cell disease. The study quantifies neurodegeneration-associated and mitochondrial proteins in a cohort of 90 sex- and age-matched adults comprising 30 healthy controls, 30...